A Study of MT-0169 in Participants With Relapsed or Refractory Multiple Myeloma or Non-Hodgkin Lymphoma
Summary
Third Opinion Trial Synopsis:
This study is for a new drug called MT-0169 which is used to treat people who have cancer called multiple myeloma or non-Hodgkin lymphoma that has come back after treatment or that does not respond to treatment. This new drug recognizes and sticks to a part of cancer cells called CD38. It will then give the cancer cells a special toxin that will kill them.
This study is for a new drug called MT-0169 which is used to treat people who have cancer called multiple myeloma or non-Hodgkin lymphoma that has come back after treatment or that does not respond to treatment. This new drug recognizes and sticks to a part of cancer cells called CD38. It will then give the cancer cells a special toxin that will kill them.
*Third Opinion AI Generated Synopsis
Trial Summary
This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.
This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma. MT-0169 is an investigational drug that recognizes and binds to the CD38 receptor, which may be found on the surface of multiple myeloma and non-Hodgkin lymphoma cancer cells. It delivers a dose of a modified toxin that kills these cells.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: